# International Neuroblastoma Response Criteria (2017 revision)

Source: https://onco.cc/terms/inrc-2017/  
OnCo record `inrc-2017` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The neuroblastoma response criteria combine the primary tumour, any spread to bone or soft tissue, and the bone marrow into one overall response for a child's treatment.

## Summary

The 2017 revision (Park and colleagues, Journal of Clinical Oncology), from an NCI clinical trials planning meeting with investigators from 13 countries, integrates response in the primary tumour, soft tissue and bone metastases, and bone marrow. Soft tissue sites are assessed with RECIST and MIBG scans, or FDG PET if the tumour does not take up MIBG; MIBG or FDG PET replaces bone scintigraphy for bone disease; marrow is assessed by histology and cytology, with 5% or less involvement classed as minimal disease; urinary catecholamines are no longer used. Overall response is complete, partial, minor, stable or progressive.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: INRC; INRC 2017; International Neuroblastoma Response Criteria

## Sources

- Park et al., Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the NCI Clinical Trials Planning Meeting (J Clin Oncol 2017): https://doi.org/10.1200/jco.2016.72.0177

## Connected records

- terms: [MIBG Curie and SIOPEN scores](https://onco.cc/terms/curie-siopen-score/), [RECIST](https://onco.cc/terms/recist/)
- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- technologies: [FDG PET](https://onco.cc/technologies/fdg-pet/), [MIBG imaging and 131I-MIBG therapy](https://onco.cc/technologies/mibg-theranostics/)

---
JSON: https://onco.cc/api/v1/entities/inrc-2017.json